Timing of surgery and bevacizumab therapy in neurosurgical patients with recurrent high grade glioma

Journal of Clinical Neuroscience

Volumn 22, Issue 1, 2015, Pages 35-39

  Abrams, Daniela Alexandru ^a,b   Hanson, Joseph A ^a,b   Brown, Justin M ^c   Hsu, Frank P K ^a   Delashaw, Johnny B ^a   Bota, Daniela A ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bevacizumab; Recurrent glioblastoma multiforme; Surgery

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CYCLOPHOSPHAMIDE; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; TEMOZOLOMIDE; ANGIOGENESIS INHIBITOR;

CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; COLORECTAL CANCER; CRANIOTOMY; DRUG EFFICACY; DRUG SAFETY; GLIOBLASTOMA; HUMAN; HYPOFRACTIONATED STEREOTACTIC RADIOTHERAPY; LIQUORRHEA; NEUROSURGERY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); POSTOPERATIVE CARE; PREOPERATIVE TREATMENT; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RETREATMENT; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; STEREOTACTIC PROCEDURE; SURGICAL PATIENT; SYSTEMATIC REVIEW; TIME TO TREATMENT; TREATMENT DURATION; TREATMENT WITHDRAWAL; TUMOR RECURRENCE; WOUND DEHISCENCE; WOUND HEALING; CHEMICALLY INDUCED; GLIOMA; PATHOLOGY; POSTOPERATIVE COMPLICATIONS;

ANGIOGENESIS INHIBITORS; BEVACIZUMAB; GLIOMA; HUMANS; NEOPLASM RECURRENCE, LOCAL; POSTOPERATIVE COMPLICATIONS;

EID: 84920664441     PISSN: 09675868     EISSN: 15322653     Source Type: Journal    
DOI: 10.1016/j.jocn.2014.05.054     Document Type: Review

References (42)

1. P. Kleihues, and W.K. Cavenee Pathology and genetics of tumours of the nervous system 2000 International Agency for Research on Cancer
2. G.N. Fuller, and B.W. Scheithauer The 2007 revised World Health Organization (WHO) classification of tumours of the central nervous system: newly codified entities Brain Pathol 17 2007 304 307
3. K.R. Hess, K.R. Broglio, and M.L. Bondy Adult glioma incidence trends in the United States, 1977-2000 Cancer 101 2004 2293 2299
4. T.A. Dolecek, J.M. Propp, and N.E. Stroup CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009 Neuro Oncol 14 2012 v1 49
5. E.R. Laws, I.F. Parney, and W. Huang Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project J Neurosurg 99 2003 467 473
6. J.C. Buckner Factors influencing survival in high-grade gliomas Semin Oncol 30 2003 10 14
7. M. Lacroix, D. Abi-Said, and D.R. Fourney A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival J Neurosurg 95 2001 190 198
8. R. Stupp, M.E. Hegi, and W.P. Mason Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial Lancet Oncol 10 2009 459 466
9. L. Stewart Chemotherapy in adult high-grade glioma: a systematic review and meta-Analysis of individual patient data from 12 randomised trials Lancet 359 2002 1011 1018
10. R. Stupp, W.P. Mason, and M.J. van den Bent Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 2005 987 996
11. A. Omuro, T.A. Chan, and L.E. Abrey Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma Neuro Oncol 15 2013 242 250
12. E.T. Wong, and S. Brem Taming glioblastoma by targeting angiogenesis: 3 years later J Clin Oncol 29 2011 124 126
13. M.H. Cohen, Y.L. Shen, and P. Keegan FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme Oncologist 14 2009 1131 1138
14. M.C. Chamberlain Bevacizumab for the treatment of recurrent glioblastoma Clin Med Insights Oncol 5 2011 117 129
15. S. Brem, R. Cotran, and J. Folkman Tumor angiogenesis: a quantitative method for histologic grading J Natl Cancer Inst 48 1972 347 356
16. A. Salmaggi, M. Eoli, and S. Frigerio Intracavitary VEGF, bFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma J Neurooncol 62 2003 297 303
17. M.C. Chamberlain Bevacizumab plus irinotecan in recurrent glioblastoma J Clin Oncol 26 2008 1012 1013 [author reply 1013]
18. Avastin [package insert]. South San Francisco, CA: Genentech Inc.
19. I. Kumar, C.A. Staton, and S.S. Cross Angiogenesis, vascular endothelial growth factor and its receptors in human surgical wounds Br J Surg 96 2009 1484 1491
20. D.A. Reardon, J.E. Herndon II, and K.B. Peters Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients Br J Cancer 107 2012 1481 1487
21. C.J. Allegra, G. Yothers, and M.J. O'Connell Initial safety report of NSABP C-08: a randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer J Clin Oncol 27 2009 3385 3390
22. H. Hurwitz, L. Fehrenbacher, and T. Cartwright Wound healing/bleeding in metastatic colorectal cancer patients who undergo surgery during treatment with bevacizumab J Clin Oncol 22 2004 3702
23. D.A. August, D. Serrano, and E. Poplin "Spontaneous", delayed colon and rectal anastomotic complications associated with bevacizumab therapy J Surg Oncol 97 2008 180 185
24. S.B. Kesmodel, L.M. Ellis, and E. Lin Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases J Clin Oncol 26 2008 5254 5260
25. B. Gruenberger, D. Tamandl, and J. Schueller Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer J Clin Oncol 26 2008 1830 1835
26. J.P. Erinjeri, A.J. Fong, and N.E. Kemeny Timing of administration of bevacizumab chemotherapy affects wound healing after chest wall port placement Cancer 117 2011 1296 1301
27. W.J. Zawacki, T.G. Walker, and E. DeVasher Wound dehiscence or failure to heal following venous access port placement in patients receiving bevacizumab therapy J Vasc Interv Radiol 20 2009 624 627 [quiz 571]
28. M.D. Moen Bevacizumab: in previously treated glioblastoma Drugs 70 2010 181 189
29. A. Lai, A. Tran, and P.L. Nghiemphu Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme J Clin Oncol 29 2011 142 148
30. P.H. Gutin, F.M. Iwamoto, and K. Beal Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas Int J Radiat Oncol Biol Phys 75 2009 156 163
31. A. Narayana, J.G. Golfinos, and I. Fischer Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma Int J Radiat Oncol Biol Phys 72 2008 383 389
32. A. Narayana, P. Kelly, and J. Golfinos Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival J Neurosurg 110 2009 173 180
33. J.J. Vredenburgh, A. Desjardins, and J.E. Herndon II Bevacizumab plus irinotecan in recurrent glioblastoma multiforme J Clin Oncol 25 2007 4722 4729
34. H.S. Friedman, M.D. Prados, and P.Y. Wen Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma J Clin Oncol 27 2009 4733 4740
35. M.C. Chamberlain, and S.K. Johnston Salvage therapy with single agent bevacizumab for recurrent glioblastoma J Neurooncol 96 2010 259 269
36. A.J. Clark, N.A. Butowski, and S.M. Chang Impact of bevacizumab chemotherapy on craniotomy wound healing J Neurosurg 114 2011 1609 1616
37. T.S. Armstrong, P.Y. Wen, and M.R. Gilbert Management of treatment-Associated toxicites of anti-Angiogenic therapy in patients with brain tumors Neuro Oncol 14 2012 1203 1214
38. M.G. Tonnesen, X. Feng, and R.A. Clark Angiogenesis in wound healing J Investig Dermatol Symp Proc 5 2000 40 46
39. F.A. Scappaticci, L. Fehrenbacher, and T. Cartwright Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab J Surg Oncol 91 2005 173 180
40. G.M. Barbagallo, M.D. Jenkinson, and A.R. Brodbelt 'Recurrent' glioblastoma multiforme, when should we reoperate? Br J Neurosurg 22 2008 452 455
41. M. Weller, T. Cloughesy, and J.R. Perry Standards of care for treatment of recurrent glioblastoma-Are we there yet? Neuro Oncol 15 2013 4 27
42. C.R. Gordon, Y. Rojavin, and M. Patel A review on bevacizumab and surgical wound healing: an important warning to all surgeons Ann Plast Surg 62 2009 707 709